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Recent studies have shown that tissue-specific stem cells (SCs) found throughout the body respond differ-
entially to DNA damage. In this review, we will discuss how different SC populations sense and functionally
respond to DNA damage, identify various common and distinct mechanisms utilized by tissue-specific SCs
to address DNA damage, and describe how these mechanisms can impact SC genomic integrity by poten-
tially promoting aging, tissue atrophy, and/or cancer development. Finally, we will discuss how similar mech-
anisms operate in cancer stem cells (CSCs) and can mediate resistance to chemo- and radiotherapy.Stem cells (SCs) are often referred to as the mother of all cells,
meaning they sit at the apex of a cellular hierarchy and, upon
differentiation, give rise to all the mature cells of a tissue (Rossi
et al., 2008). More specifically, SCs are described as having
the unique capacity to self-renew, in order to establish and
replenish the SC pool, and also to differentiate, thereby gener-
ating progeny that carry out specific tissue functions. SCs are
essential for specification and morphogenesis of tissues during
embryonic development (organogenesis) and for the mainte-
nance and repair of adult tissues throughout life by replacing
cells lost during normal tissue turnover (homeostasis) or after
injury. Although tissue-specific SCs are found in many highly
regenerative organs, such as blood, skin, and the digestive tract,
they are also found in nonrenewing organs such as muscle,
where they allow repair after tissue damage.
Like every other cell in the body, SCsmust constantly contend
with genotoxic insults arising from both endogenous chemical
reactions, such as reactive oxygen species (ROS) generated
by cellular metabolism, and exogenous insults coming from their
surrounding environment (Sancar et al., 2004). It has been esti-
mated that every cell undergoes about 100,000 spontaneous
DNA lesions per day (Lindahl, 1993). As SCs ensure the lifetime
maintenance of a given tissue, anymisrepair of DNA damage can
be transmitted to their differentiated daughter cells, thereby
compromising tissue integrity and function. Consequently,
mutations that diminish the renewal and/or differentiation poten-
tial of SCs can result in tissue atrophy and aging phenotypes,
whereas mutations providing a selective advantage to the
mutated cells can lead to cancer development (Rossi et al.,
2008).
As such, a delicate balance must be struck to prevent exhaus-
tion and transformation of the SC pool while maintaining the
ability of SCs to preserve homeostasis and to respond to injury
when necessary. To fulfill these demands, the numbers of SCs
and their functional quality must be strictly controlled through
a balance of cell-fate decisions (self-renewal, differentiation,
migration, or death), which are mediated by a complex network
of cell-intrinsic regulation and environmental cues (He et al.,
2009; Weissman, 2000). Specific protective mechanisms also16 Cell Stem Cell 8, January 7, 2011 ª2011 Elsevier Inc.ensure that SC genomic integrity is well preserved and include
localization to a specific microenvironment, resistance to
apoptosis, limitation of ROS production, and maintenance in
a quiescent state (Orford and Scadden, 2008; Rossi et al.,
2008). Altogether, these attributes of SCs ensure tissue mainte-
nance and function throughout the lifetime of an organism, while
limiting atrophy and cancer development.
DNA-Damage Response
All living cells, including tissue-specific SCs, must constantly
contend with DNA damage (Sancar et al., 2004) (Figure 1). Due
to its chemical structure, DNA is particularly sensitive to sponta-
neous hydrolysis reactions which create abasic sites and base
deamination. Furthermore, ongoing cellular metabolism gener-
ates ROS and their highly reactive intermediate metabolites,
which can create 8-oxoguanine lesions in DNA as well as
a variety of base oxidations and DNA strand breaks that are all
highly mutagenic and can lead to genomic instability. DNA is
also constantly assaulted by mutagens present in the external
environment. UV light from the sun, as well as various chemical
reagents, can react with DNA and induce nucleotide chemical
modifications. Ionizing radiations (IR) generated by the cosmos,
X-rays, and exposure to radioactive substances, as well as treat-
ment with certain chemotherapeutic drugs, can induce base
modifications, interstrand crosslinks, single- and double-strand
breaks (DSBs), which can all lead to genomic instability.
Consistent with the wide diversity of potential DNA lesions,
eukaryotic cells exhibit many highly conserved DNA repair
mechanisms that can recognize and repair different types of
DNA damage with varying fidelity and mutagenic consequences
(Lombard et al., 2005) (Figure 1). For instance, base modifica-
tions induced by spontaneous chemical reactions and ROS-
mediated DNA lesions are repaired by base excision repair
(BER), whereas nucleotide modifications induced by chemicals
and UV light are repaired by the nucleotide excision repair
(NER) pathway. The pathways that mediate the repair of DSBs
vary depending on the cell-cycle status of the damaged cells.
During the G0/G1 phase, DSBs are repaired by the nonhomolo-
gous end-joining (NHEJ) pathway, while, during the S-G2/M
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Figure 1. DNA-Repair Pathways in Mammalian Cells
Each type of DNA assault results in a different type of lesion, which can be repaired with different fidelity by distinct and highly specialized repair pathways.
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nation (HR) pathway. These two modes of DNA repair are not
equally faithful. HR is an error-free DNA repair mechanism due
to the use of the other intact strand as a template, while NHEJ
is an error-prone repair mechanism, which may result in small
deletions, insertions, nucleotide changes, or chromosomal
translocations due to the absence of an intact template for
repair. Lastly, replication errors leading to insertion, deletion,
and base misincorporation resulting in base mispairing are cor-
rected by the mismatch repair (MMR) pathway.
Irrespective of the type of lesion and the repair mechanism,
DNA damage is rapidly sensed and activates evolutionarily
conserved signaling pathways, known collectively as the DNA-
damage response (DDR), whose components can be separated
into four functional groups: damage sensors, signal transducers,
repair effectors, and arrest or death effectors (Sancar et al.,
2004) (Figure 2). Ultimately, activation of DDR leads to the
phosphorylation and stabilization of p53, inducing its nuclear
accumulation and upregulation of its target genes (d’Adda di
Fagagna, 2008). Depending upon the extent of DNA damage,
the type of cell undergoing DNA damage, the rapidity of DNA
repair, the stage of the cell cycle, the strength and the duration
of p53 activation, and the genes transactivated by p53, cellscan either undergo transient cell-cycle arrest (through induction
of the cyclin-dependant kinase inhibitor p21), programmed cell
death (through induction of the pro-apototic bcl2 gene family
members bax, puma and noxa), or senescence (through induc-
tion of the cyclin-dependant kinase inhibitor p16/Ink4a and the
tumor suppressor gene p19/ARF).
Diversity of DNA Repair Mechanisms in Tissue-Specific
Stem Cells
The critical role of the different DNA repair mechanisms for over-
all tissue integrity and function is well illustrated by the severe
clinical consequences observed in both humans and mice for
mutations in genes regulating these pathways (Hakem, 2008).
The involvement of tissue-specific SCs in mediating such symp-
toms and the role of the diverse DNA-damage recognition and
DNA-repair mechanisms in maintaining tissue-specific SC func-
tion is now starting to emerge (Kenyon and Gerson, 2007).
Defects in DSB recognition machinery lead to premature
aging, neurodegeneration, and increased cancer susceptibility.
ATM (ataxia-telengiectasia mutated), ATR (ATM and Rad3
related), and DNA-PKs are DNA-damage-sensing protein
kinases that, through a series of phosphorylation events, signal
the presence of DNA lesions and initiate DNA repair or cell-cycleCell Stem Cell 8, January 7, 2011 ª2011 Elsevier Inc. 17
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Pathways
Upon DNA damage, distinct factors detect, trans-
mit, and amplify the DNA-damage signal. DNA
double-strand breaks can be repaired by homolo-
gous recombination (mediated among other
factors by the MRN complex, ATM, and Brca1)
or by nonhomologous end-joining (in which the
Ku70/Ku80/DNA-PKcs complex plays a major
role). This DNA-damage response converges
upon p53 which, depending on the target genes
activated, regulates different cellular outcomes.
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vessel abnormalities, cerebelar degeneration, immunodefi-
ciency, and increased risk of cancers (Hoeijmakers, 2009).
Mice lacking Atm, like ATM patients, are extremely sensitive to
IR exposure and have decreased somatic growth, neurological
abnormalities, decreased T cell numbers, and exhibit premature
hair graying and infertility (Barlow et al., 1996). Many of these
phenotypes can be linked to defects in SC function, which high-
lights the critical role of this DDR component for the survival and
preservation of various SC compartments. Atm-deficient hema-
topoietic SCs (HSCs) harbor increased ROS levels and display
an overall decrease in number and function over time, leading
to eventual hematopoietic failure (Ito et al., 2004, 2006).Atm defi-
ciency also sensitizes mice to IR-induced prematuremelanocyte
SC differentiation, resulting in hair graying (Inomata et al., 2009).
Germ cell development is also altered in Atm-deficient mice, and
mutant animals experience a progressive loss in germ SCs
(spermatogonia) and become infertile (Takubo et al., 2008).
Mutations in ATR also cause developmental defects in mice
(pregastrulation lethality) and humans (Seckel syndrome)
(Hakem, 2008; Hoeijmakers, 2009; Seita et al., 2010). Condi-
tional deletion of Atr in adult mice leads to the rapid appearance18 Cell Stem Cell 8, January 7, 2011 ª2011 Elsevier Inc.of age-related phenotypes, such as hair
graying, alopecia, kyphosis, osteopo-
rosis, thymic involution, and fibrosis,
which are associated with SC defects
and exhaustion of tissue renewal and
homeostatic capacity (Brown and Balti-
more, 2000; Ruzankina et al., 2007).
The MRE11, RAD50, and NBS1 (MRN)
complex senses DSBs, unwinds the
damaged region of DNA, serves as part
of the repair scaffolding, and induces
downstream signaling including ATM
activation (Figure 2). Deletion of any
component of the MRN complex results
in embryonic lethality in mice (Hakem,
2008). However,micebearing ahypomor-
phic Rad50k22m mutation are viable but
die around 2.5 months from of B cell
lymphoma or bone marrow failure due,
in part, to p53-dependent DDR-mediated
apoptosis and loss of HSC function
(Bender et al., 2002). Moreover, muta-
tions in BRCA1 and BRCA2, two DSB
mediators that trigger DNA repair throughthe HR pathway (Figure 2), lead to a major increase in the risk of
developing breast and ovarian cancers in women, which, at least
in the breast, has recently been linked to the accumulation of
genetically unstable mammary SCs (Liu et al., 2008).
While no spontaneous mutations in NHEJ pathway compo-
nents have been reported so far in human syndromes associated
with premature aging or increased risk of cancers, the inactiva-
tion of various NHEJ genes in mice has demonstrated their
essential function in lymphocyte development and prevention
of lymphoma. The core components of the NHEJ repair pathway
include the end-binding and end-processing proteins Ku70,
Ku80, DNA-PKcs, and Artemis, as well as the ligation complexes
XRCC4, LigIV, and Cerrunos (Lombard et al., 2005). As NHEJ is
critical for V(D)J recombination during lymphocyte maturation,
many of the mutant mouse models deficient in particular NHEJ
components exhibit arrested lymphoid development. Mice
carrying a Lig4y288c hypomorphic mutation also display growth
retardation, immunodeficiency, and pancytopenia associated
with severe HSC defects (Kenyon and Gerson, 2007; Nijnik
et al., 2007). Mice lacking the end-binding and end-processing
components of NHEJ, Ku70, and Ku80 have stress-induced
HSC self-renewal defects associated with poor transplantability,
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lineage differentiation (Kenyon and Gerson, 2007; Rossi et al.,
2007).
Mutations in NER pathway components induce human
syndromes known as Xeroderma Pigmentosum (XP), Cockayne
syndrome (CS), and Trichothiodistrophy (TTD), which are char-
acterized by premature aging, neurodegeneration, and extreme
photosensitivity, especially in XP syndromes (Hoeijmakers,
2009). XP patients often completely lack NER repair activity
and have increased incidence of skin cancer, while CS and
TTD patients have defects in transcription-coupled repair, which
has little mutagenic effect because it only deals with lesions in
the transcribed strand. Mice expressing XPDTTD, a mutated
formof an essential NER component, have decreasedHSC func-
tionwith reduced self-renewal potential and increased apoptosis
levels (Rossi et al., 2007). Mice deficient in Ercc1, a component
of both NER and intrastrand crosslink (ICL) repair, die within
4 weeks of birth, have multilineage hematopoietic cytopenia
due to progenitor depletion, HSC senescence, and a defective
response to DNA crosslinking by mitomycin C (Hasty et al.,
2003; Prasher et al., 2005).
Mutations in MMR pathway components induce hereditary
nonpolyposis human colorectal cancer known as Lynch
syndrome, which presents with about an 80% lifetime risk of
developing colorectal cancers as well as other malignancies
(Hoeijmakers, 2009). Mice mutant for genes important for the
MMR pathway, including Msh2 and Mlh1, also display higher
frequencies of hematological, skin, and gastrointestinal tumors,
consistent with a critical role of the MMR in preventing accumu-
lations of oncogenic mutations (Hakem, 2008). In addition, mice
lacking Msh2 exhibit defective HSC activity, with enhanced
microsatellite instability observed in their progeny (Reese et al.,
2003).
Other human conditions associated with defects in DNA-
damage recognition and repair pathways include Fanconi’s
Anemia (genetic defects in the FANC family of proteins), Bloom’s
or Werner’s syndromes (both caused by mutations in DNA heli-
cases), and a range of diseases associated with telomerase
dysfunction and telomere instability (Kenyon and Gerson,
2007). These diseases are not specifically reviewed here, but
their complex pathologies involve defects in various tissue-
specific SCs.
DNA-Damage Response in Tissue-Specific SCs
While tissue-specific SCs share the same purpose of maintain-
ing organ functionality, recent studies have shown that the
mechanisms of their responses to DNA damage, the outcome
of their DDR, and the consequences of DNA repair for their
genomic stability vary greatly between tissues.
Hematopoietic SCs
The hematopoietic (blood) system is one of the best-studied
adult tissues in terms of its hierarchical development, in that all
blood cell lineages derive from a small number of quiescent
HSCs via a highly proliferative amplifying progenitor compart-
ment (Orkin and Zon, 2008). Being a highly regenerative
compartment, it is also one of the most radiosensitive tissues
in the body (<4 Gy), and one of the first organ systems to fail after
total body irradiation. IR exposure differentially affects hemato-
poietic cells depending on their state of maturity, with HSCsbeing more radioresistant than their downstream progeny
(Meijne et al., 1991). By comparing thewayHSCs and their differ-
entiated progeny respond to low doses of IR (2 to 3 Gy), recent
work has begun to clarify the ways in which HSCs at different
stages of ontogeny deal with DNA damage and the mutagenic
consequences of different DNA repair mechanisms in this
tissue-specific SC population (Figure 3A).
HSCs are specified in the aorta-gonad-mesonephros (AGM)
region of the developing fetus, are actively expanded in several
anatomic locations, including the liver and placenta, during fetal
development, and are finally seeded in the bone marrow cavity
during late embryogenesis. In the bone marrow, HSCs progres-
sively mature after birth to become the quiescent adult HSCs
that are maintained during the lifetime of the organism. Fetal
and adult HSCs differ in many aspects of their biological regula-
tion, including cell-cycle status and transcriptional control (Orkin
and Zon, 2008). Using human umbilical cord blood (CB)-derived
HSCs, which are highly proliferative, circulating cells that are still
considered to be of fetal origin, Milyavsky and colleagues found
that irradiated (3 Gy) CB-derived HSCs had a slower rate of DSB
repair than more mature progenitors and increased levels of
apoptosis mediated in part through the ASPP1 protein, which
could be reversed if p53 expression was silenced or bcl2 expres-
sion was enhanced (Milyavsky et al., 2010). Upon primary trans-
plantation, irradiated CB-derived HSCs could not successfully
engraft into immunodeficient mice. In contrast, irradiated cells
with disabled p53 or bcl2 overexpression could be serially trans-
planted, albeit with decreased efficiency compared to nonirradi-
ated normal cells. In this context, transplanted CB-derived HSCs
with disabled p53 reconstituted even less well than cells with
bcl2 overexpression, and their progeny harbored high levels of
DSBs that were not observed in the progeny of bcl2 overex-
pressing cells. This study emphasizes the role of p53-mediated
DDR and the Bcl2 family of prosurvival genes in HSC function
(Asai et al., 2010; Seita et al., 2010; Weissman, 2000), and indi-
cates that the main outcome of the DDR in fetal HSCs is induc-
tion of apoptosis and overt cell elimination (Figure 3A). On the
other hand, using adult mouse HSCs that are kept mostly quies-
cent within the bone marrow cavity, Mohrin and colleagues
showed a very different response to irradiation, with overt cell
survival and DNA repair being the main outcomes of the DDR
(Mohrin et al., 2010). Adult HSCs, either quiescent or induced
to proliferate by cytokine pretreatment, engage specialized
response mechanisms that protect them from low doses of IR
(2 Gy). In quiescent HSCs, these mechanisms include enhanced
prosurvival gene expression (bcl2, bcl-xl, mcl1, a1), which
inhibits cell death induced by p53 proapototic genes (bax,
noxa, puma), likely allowing p53-mediated induction of p21 to
engage a transient growth-arrest response and to permit DNA
repair. While the exact mechanism of the survival response in
proliferating HSCs is less clear, they were found to be as radio-
resistant as quiescent HSCs (Mohrin et al., 2010). Dictated by
their cell-cycle status, proliferating HSCs use the high-fidelity
HR pathway to repair DSBs, while quiescent HSCs employ the
error-prone NHEJ pathway. Irradiated quiescent HSCs display
high levels of chromosomal abnormalities when compared to
proliferating HSCs, and their progeny show persistent genomic
instability associated with misrepaired DNA and engraftment
defects in secondary recipient mice. Since NHEJ appears toCell Stem Cell 8, January 7, 2011 ª2011 Elsevier Inc. 19
AQuiescent adult mouse
bone marrow
hematopoietic SCs
Proliferating human
umbilical cord blood 
hematopoietic SCs
DNA repair
NHEJ
Mcl1
Bcl-xl
Bcl2, a1
Cell
death
 SC Survival
p21
Cell cycle 
arrest
DNA
repair
Bcl2
Cell
death
SC depletion
DNA damage
ASSP1
Genetic 
instability
p53 p53
Quiescent 
and proliferating
adult mouse 
hair follicle 
bulge SCs
DNA repair
NHEJ
DNA-PK
Bcl2
Cell
death
 SC Survival
p21
 
Cell cycle
arrest
Genetic
instability
DNA damage
?
p53
B
Figure 3. DNA-Damage Response in Hematopoietic and Hair Follicle Bulge Stem Cells
(A) Human umbilical cord blood-derived HSCs and mouse bone marrow-derived HSCs exhibit opposite outcomes following irradiation-induced DNA damage,
with different consequences for their overall maintenance and genomic integrity.
(B) Upon irradiation, mouse hair follicle bulge stem cells exhibit transient p53 activation due, in part, to high levels of DNA-PK-mediated NHEJ repair and higher
Bcl2 expression that block apoptosis, resulting in enhanced survival.
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quiescent HSCs, these results help explain why most mouse
models lacking functional components of DSB recognition and
repair pathways undergo hematopoietic failure upon genotoxic
stress (Hakem, 2008). Moreover, this study indicates that while
adult HSCs, in contrast to fetal HSCs, may survive DNA-
damaging insults, they do not emerge unscathed (Figure 3A),
which might have direct implications for aging and cancer devel-
opment. It may also explain why cancer patients treated with
radiotherapy or chemotherapy may develop leukemias and
lymphomas (blood cancer) or myelodysplasias (bone marrow
failure) because the use of error-prone DNA repair in quiescent
HSCs may be at the heart of these dangerous side effects of
cancer treatment.
Taken together, these two studies (Milyavsky et al., 2010;
Mohrin et al., 2010) unveil some striking differences in the
outcome of irradiation-induced DDR in HSCs from different
species and at different developmental stages. While it is
possible that different organisms with vastly different lifespans
have evolved distinct strategies to cope with DNA damage, it
is tempting to speculate that these differences reflect an adapta-
tion in the stress responsemechanisms used by HSCs at distinct
stages of ontogeny to ensure optimal function of the blood
system. During embryogenesis and until birth, the goal is to
expand the SC population while protecting its genomic integrity
in order to establish a pool of pristine HSCs that will ensure blood
homeostasis for the lifetime of the organism. In this context, the
efficient elimination of irradiated human CB-derived HSCs
described by Milyavsky and colleagues fulfill this demand by
eliminating damaged fetal HSCs that could be detrimental to
the organism and its reproductive purpose. Conversely, in20 Cell Stem Cell 8, January 7, 2011 ª2011 Elsevier Inc.adults, the main function of the HSC compartment is to preserve
blood homeostasis and to quickly respond to hematopoietic
needs (blood loss, infection, etc.). The fact that adult HSCs
reside in hypoxic niches in the BM cavity and are mostly kept
in a quiescent phase of the cell cycle contribute to their overall
maintenance (self-renewal) and protect their genomic integrity
(fitness) by minimizing DNA damage associated with ROS
production, cellular respiration, and cell division (Orford and
Scadden, 2008; Rossi et al., 2007). In this context, the survival
and efficient DNA repair of irradiated mouse adult HSCs
described by Mohrin and colleagues fulfills the same purpose
by protecting the most important cells of the tissue. Since both
quiescent and proliferating mouse adult HSCs show similar
radioresistance, it is likely that the radiosensitivity displayed by
human CB-derived HSCs reflect cell-intrinsic differences in
transcriptional programs or chromatin states between HSCs at
various stages of development. Additional investigations are
clearly needed to fully understand the mechanisms underlying
these differences in DDR outcomes between fetal and adult
HSCs.
However, the short-term survival strategy used by adult HSCs
likely comes at a cost for their long-term genomic integrity. While
quiescence is one of the very mechanisms that protects adult
HSC function, it also renders damaged HSCs intrinsically vulner-
able to mutagenesis because it forces them to use the error-
prone NHEJ pathway to repair DSBs, thereby increasing the
risk of creating mutations in this self-renewing population. In
fact, the accrual of chromosomal translocations resulting from
unfaithful DNA repair following DSBs is a hallmark of human
blood malignancies (Look, 1997). Such accumulation over time
of NHEJ-mediated mutations may hinder cellular performance
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ring with age in the HSC compartment and to the development
of age-related hematological disorders (Rossi et al., 2007).
Epidermal SCs
The skin epidermis is composed by the juxtaposition of themany
pilosebaceous units consisting of a hair follicle, its associated
sebaceous gland, and its surrounding interfollicular epidermis.
Different classes of SCs ensure homeostasis of the skin
epidermis (Blanpain and Fuchs, 2009). Multipotent hair follicle
bulge SCs (BSCs) contribute to the cyclic regeneration of the
hair follicle and to the repair of the interfollicular epidermis
following wounding. In the absence of injury, the interfollicular
epidermis can self-renew independently of BSCs through the
presence of unipotent progenitors scattered throughout the
basal region of the epidermis. Specialized SCs and progenitor
cells are also found in the infundibulum and sebaceous glands
(Blanpain and Fuchs, 2009).
Since the epidermis serves as a barrier between the body and
the external environment, it is constantly assaulted by genotoxic
stress such as UV irradiation. As discussed earlier, UV radiation
causes the formation of thymidine dimers, (6-4) pyrimidine
photoproducts, and ROS-induced DNA lesions that are repaired
by the NER, NHEJ, or HR pathways, depending on the type of
damage and the state of the cell cycle. Upon UV irradiation,
basal epidermal cells exhibit sustained p53 activation compared
to the more differentiated suprabasal cells (Finlan et al., 2006).
Following chronic administration of UV radiation, slow-cycling
SCs and progenitor cells of the infundibulum and sebaceous
glands also retain UV-induced photoproducts longer than
more differentiated cells of the epidermis, suggesting a decrease
in the repair activity of these cells (Nijhof et al., 2007). Recently,
Nrf2 has been shown to regulate the expression of critical
regulators of oxidative stress (such as several enzymes of the
glutathione metabolism) and to protect the epidermis from UV-
induced apoptosis. The gradient of apoptosis levels observed
between basal (high) and suprabasal (low) cells following UV irra-
diation is inversely correlated with Nrf2 expression. Surprisingly,
while Nrf2 overexpression protects basal cells from UV induced
apoptosis, it does not decrease the proportion of cells that
harbor thymidine dimers. In addition, suprabasal expression of
Nrf2 offers some protection from UV-induced apoptosis to basal
cells through a paracrine mechanism (Schafer et al., 2010).
These data indicate that proliferative cells of the interfollicular
epidermis are more sensitive to UV-mediated apoptosis relative
to their more committed progeny.
While the skin epidermis is more radioresistant than the blood
system, acute administration of more than 5 Gy results in severe
skin reactions consisting of inflammation (erythema) and loss of
differentiated skin layers (desquamation) that rapidly appear
following IR, whereas hair loss and chronic ulcerations appear
with a delay of 2 to 3 weeks after IR administration. The sensi-
tivity of the epidermis to IR is also illustrated by the common
side effects of radiotherapy, which include acute and chronic
dermatitis and an increased incidence of skin cancer (Gold-
schmidt and Sherwin, 1980). While the field is still in search of
specific cell-surface markers that will allow high purity isolation
of interfollicular epidermal progenitors, a combination of
markers, including a6 integrin and CD71, have been used to
enrich SCs from the mouse and human interfollicular epidermis(Li et al., 1998; Tani et al., 2000). Following exposure to low
doses of IR, rapidly cycling human epidermal progenitor cells
(a6Hhi/CD71+) undergo apoptosis and display decreased
in vitro colony forming efficiency, whereas slow-cycling human
epidermal SCs (a6H/CD71) were resistant to IR-induced cell
death (Rachidi et al., 2007). The enhanced survival of human
epidermal SCs upon IR exposure has been linked to a higher
secretion of FGF2 following DNA damage, which increases
DNA repair activity in epidermal SC by autocrine/paracrine
mechanisms (Harfouche et al., 2010). While these studies have
been performed ex vivo, Sotiropoulou and colleagues have
recently investigated how epidermal cells respond to DNA
damage within their native niche and showed that multipotent
hair follicle BSCs, like HSCs, are more resistant to DNA-
damage-induced cell death compared to the other cells of the
epidermis (Sotiropoulou et al., 2010). At least two important
mechanisms contribute to the higher resistance of BSCs to
IR-mediated DNA damage (Figure 3B), both which are indepen-
dent of the relative quiescence of these cells and of the induction
of premature senescence. First, BSCs express higher levels of
the antiapoptotic protein Bcl2, and the proportion of BSCs
undergoing apoptosis is increased in bcl2 null mice, demon-
strating that similar to HSCs, a higher expression of prosurvival
factors contributes to the resistance of BSCs to apoptosis. The
other contributing mechanism is the transient nature of DDR
activation in BSCs. Soon after IR exposure, p53 is expressed
in the nuclei of almost all epidermal cells, including BSCs, and
is required for DNA-damage-induced cell death in the epidermis
(Botchkarev et al., 2000; Song and Lambert, 1999; Sotiropoulou
et al., 2010). However, unlike other cells of the epidermis, the
number of BSCs expressing p53 is greatly decreased by 24 hr
following irradiation, and mutant mice exhibiting sustained
expression of p53 show increased IR-induced apoptosis in
BSCs. This indicates that the short duration of IR-mediated
p53 activation promotes BSC survival following DNA damage.
Interestingly, BSCs also display accelerated DNA repair and
enhancedNHEJ repair activity. In SCIDmice, which have amuta-
tion in DNA-PK and thus exhibit decreased NHEJ activity, BSCs
are radiosensitive, suggesting that accelerated NHEJ-mediated
DSB repair contributes to their protection against IR exposure.
The importance of DDR in BSCs is also illustrated by the SC
exhaustion and progressive alopecia that occurs in mice where
Atr has been deleted in hair follicle BSCs and their progeny
(Ruzankina et al., 2007).
Because NHEJ is an error-prone DNA repair mechanism, the
higher resistance of BSCs to DNA-damage-induced apoptosis
and the accelerated NHEJ-mediated DNA repair activity could
be, like in HSCs, a double-edged sword that promotes short-
term survival of BSCs at the expense of their long-term genomic
integrity and could potentially allow for the accumulation of
cancerous mutations (Figure 4). Consistent with this notion,
SCID mice and mice deficient for Bcl-XL, a prosurvival gene,
show decreased susceptibility to chemical carcinogenesis
(Kemp et al., 1999; Kim et al., 2009), which has been attributed
to the elimination of mutated BSCs by apoptosis.
Melanocyte SCs
Melanocytes are neural crest-derived cells responsible for the
pigmentation of skin and hair. The mature melanocytes respon-
sible for hair color are derived from melanocyte SCs (MSCs),Cell Stem Cell 8, January 7, 2011 ª2011 Elsevier Inc. 21
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Figure 4. DNA-Damage Response in Tissue-Specific Stem Cells
Common and distinct pathways of DNA-damage response in different types of tissue-specific SCs.
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cycle of hair regeneration, MSCs are stimulated to proliferate
and give rise to transit amplifying cells, which will expand in
the lower hair follicle before undergoing terminal differentiation,
which results in the integration of their pigment into the new
hair. At the end of each hair cycle, mature melanocytes undergo
apoptosis and are eliminated with the rest of the follicle, to be
subsequently replenished by the renewal and differentiation of
MSCs during the next cycle (Robinson and Fisher, 2009). Hair
graying, which is one of the most common signs of aging, results
from the depletion of MSCs from the hair follicle. The onset of
hair graying in mice and humans is accompanied by the pres-
ence of ectopically pigmented melanocytes, suggesting prema-
ture differentiation of MSCs within their niche (Nishimura et al.,
2005). Premature hair graying can also result fromahypomorphic
mutation in Mitf, the main regulator of MSC differentiation, that
results in a downregulation of bcl2 and in premature differentia-
tion of MSCs in the hair follicle (McGill et al., 2002). Bcl2 is critical
for MSCmaintenance as bcl2 null mice lose their coat pigmenta-
tion after the first hair cycle due to massive MSC apoptosis
(Nishimura et al., 2005). Premature hair graying and progressive
MSC loss also occur following administration of DNA damaging
agents such as IR, mitomycin C, or hydrogen peroxide (Inomata
et al., 2009). While the mechanisms underlying the DDR in MSCs
are not yet fully understood, p53, p16, and p19ARF, although
transiently activated by DNA damage, are not responsible for
the premature differentiation and loss of MSCs. Indeed, mice
deficient for p53 or the Ink4a locus (p16 and p19ARF) are not pro-
tected fromDNA-damage-induced hair graying, contrasting with
the requirement of p53 in mediating DNA-damage-induced cell
death in other tissue-specific SCs. In contrast, DNA damage
induces prolonged activation of the canonical differentiation
program of MSCs, including sustained upregulation of Mitf,
a key regulator of melanocyte differentiation and melanogenic
enzymes, which in turn stimulates the premature and ectopic22 Cell Stem Cell 8, January 7, 2011 ª2011 Elsevier Inc.differentiation of MSCs within their niche. The ATM checkpoint
regulator also exerts a protective function in MSCs because
Atm null mice and ATM-deficient patients exhibit premature
hair graying (Hakem, 2008) and loss of Atm sensitizes mice to
IR-induced premature MSC differentiation (Inomata et al., 2009).
Despite being located in the same hair follicle niche, BSCs and
MSCs respond very differently to DNA damage. Both types of
SCs do not senesce or commit apoptosis upon DNA damage,
but while BSCs repair their DNA rapidly and express high
levels of antiapoptotic molecules in order to avoid programmed
cell death, MSCs are eliminated by premature differentiation
(Figure 4). These different outcomes imply that cell intrinsic prop-
erties are more important than the local microenvironment in
controlling DDR in skin SCs. It is interesting to note that mela-
noma, a malignant tumor of melanocytes, does not arise from
hair follicle MSCs but rather from skin melanocytes. These cells
are located along the interfollicular epidermis, suggesting that
the premature differentiation of MSCs following DNA damage
may serve to eliminate precancerous MSCs residing in the hair
follicle.
Intestinal SCs
The intestinal tissue is very sensitive to DNA damage. Acute
whole-body irradiation (<6 Gy) induces considerable damage
to the intestine, resulting in severe diarrhea and electrolyte
imbalances, which can be lethal in extreme cases. The intestinal
lining is a simple epithelium composed of a single layer of cells
that can be divided into two compartments: the proliferative
base of the intestine, called the crypt, and the differentiated
intestinal cells forming the villi that face the intestinal lumen.
The intestinal SCs (ISCs) are localized at the bottom of the crypt,
where they proliferate to give rise to transit amplifying cells,
which are found along the crypt, and divide faster and migrate
to the upper part of the crypt where they undergo cell-cycle
arrest and terminal differentiation (Barker et al., 2010; Casali
and Batlle, 2009; Marshman et al., 2002). Although the exact
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it has long been suggested that ISCs reside at the +4 position
from the base of the crypts and that these SCs are more quies-
cent compared to the other crypt cells. Consistent with that
notion, Bmi1, which is preferentially expressed in +4 crypt cells,
induced long-term labeling of the crypto-vilus unit inBmi1CREER
reporter mice, consistent with the labeling of long-lived multipo-
tent ISCs (Sangiorgi and Capecchi, 2008). A second population
of ISCs expressing Lgr5, a leucine-rich orphan G protein-
coupled receptor and Wnt pathway activated gene, has recently
been identified (Barker et al., 2007). Lgr5+ cells cycle more
frequently than the +4 cells and are located at the bottom
of the crypt intercalated between the paneth cells. Lineage
tracing experiments using Lgr5-GFP-IRES-Cre-ERT;;RosaLacZ
reporter mice demonstrated that Lgr5+ cells give rise to all intes-
tinal cell lineages and result in the long-term labeling of the
cryptovilus unit, also consistent with the labeling of long-lived
multipotent ISCs.
ISCs are extremely sensitive to DNA damage and undergo
massive apoptosis upon low doses of irradiation (1 Gy). Interest-
ingly, while it is generally assumed that radiosensitivity is corre-
lated with cell-cycle status (Gudkov and Komarova, 2003), the
apoptosis sensitivity of intestinal crypt cells is inversely corre-
lated with their relative quiescence. The most quiescent ISCs
located at +4 position are the most sensitive to IR-induced cell
death, followed by the more active Lgr5+ ISCs, whereas the
rapidly cycling transit-amplifying cells appear to be the most
radioresistant (Barker et al., 2007; Potten et al., 2002; Wilson
et al., 1998). Different mechanisms are responsible for the
extreme sensitivity of ISCs to DNA damage, including an
enhanced activation of the p53 pathway, lower expression of
the antiapoptotic protein Bcl2 (Merritt et al., 1995), and general
lack of DNA repair activity (Potten, 2004). Upon irradiation,
expression of p53 and its downstream target genes p21 and
puma increases throughout the crypts, but the frequency of
p53-positive cells and the levels of expression of its target genes
are higher at the base of the crypt and progressively decrease
along the crypts toward the vilus (Merritt et al., 1994; Qiu et al.,
2008; Wilson et al., 1998). Furthermore, IR does not induce
apoptosis in the intestine of p53 null mice (Merritt et al., 1994;
Qiu et al., 2008; Wilson et al., 1998). IR-induced ISC apoptosis
is also blocked in puma-deficient mice, and ISC survival is pro-
longed after administration of puma antisense nucleotides,
thereby demonstrating that Puma is the main proapoptotic
target of the p53-mediated DDR in ISCs (Qiu et al., 2008). In
contrast to other SC populations described above, bcl2 expres-
sion is not detected in ISCs and irradiated bcl2 null mice only
show a modest increase in ISC apoptosis, suggesting that
Bcl2 does not play a critical role in protecting ISCs from DNA-
damage-induced cell death (Merritt et al., 1995). Finally, the
absence of an irradiation dose response of crypt degeneration
suggests that quiescent ISCs lack DNA repair capacity, thereby
increasing their propensity to undergo apoptosis following DNA
damage (Hendry et al., 1982; Potten, 2004).
The architecture of the colon resembles that of the small intes-
tine. Similar to ISCs, colonic SCs (CoSCs) are also localized at
the bottom of the crypt and express Lgr5, although CoSCs
exhibit a longer cell-cycle time than ISCs. Interestingly, the
DDR of CoSCs differs significantly from that of ISCs, with CoSCsbeing considerably more radioresistant than ISCs (Figure 4). It is
estimated that CoSCs require eight times the dose of irradiation
needed by ISCs to reach similar levels of apoptosis (Barker et al.,
2007; Potten and Grant, 1998; Pritchard et al., 2000). The greater
radioresistance of CoSCs has been attributed to a lower expres-
sion of p53 (Hendry et al., 1997; Merritt et al., 1994) and higher
expression of bcl2 (Merritt et al., 1995; Qiu et al., 2008). Further-
more, in contrast to ISCs, CoSCs from bcl2 null mice show
a much greater increase in DNA-damage-induced apoptosis,
demonstrating that bcl2 expression in CoSCs does contribute
to their higher relative radioresistance. The altruistic suicide
of ISCs in response to DNA damage could decrease the acquisi-
tion of precancerous mutations in these cells and potentially
explain the rarity of intestinal neoplasia compared to the higher
frequency of colonic cancers, despite the higher cellular turnover
of the intestine.
Germline SCs
Primordial germ cells (PGCs) are transient precursors of germ
SCs (GSCs), which uponmeiosis give rise to the gametes (sperm
and egg), which are the only cells capable of transferring genetic
information from one generation to the next (Chuva de Sousa
Lopes and Roelen, 2010; Laird et al., 2008; Richardson and
Lehmann, 2010). PGCs are specified in the embryo, migrate to
the gonadal ridges were they undergo sex determination, and
give rise to the female (oogonia) or the male (spermatogonia)
GSCs. The spermatogonia exhibit an almost unlimited life
span, remaining quiescent until puberty, at which point they re-
acquire the ability to self-renew, undergo meiosis, and produce
mature male gametes for the lifetime of the organism. In sharp
contrast, the pool of oogonia is established during embryogen-
esis, and consequently, females are born with a finite number
of oogonia.
The generation of haploid chromosomes during meiosis
requires many of the proteins involved in DNA repair (Sasaki
et al., 2010). During PGC maturation, genome-wide DNA
demethylation occurs in order to erase genomic imprinting.
DNAdemethylation inmousePGCs is initiatedby theappearance
of single-strand breaks and activation of theBERpathway,which
may be linked to deamination of methylcytosine or to other yet-
to-be-discovered mechanisms (Hajkova et al., 2010). Mutations
in the germ line can be extremely dangerous and can either
directly lead to sterility (Loft et al., 2003) or transmission of heri-
table genetic diseases by the gametes. Genetic aberrations in
GSCs may occur upon radiation exposure, such as radiotherapy
and radiological examination, or after exposure to teratogenic or
mutagenic chemicals, but the main source of DNA damage is
their normal metabolic activity and ROS production (Kujjo et al.,
2010).Microarray analysis uncovered that DNA-damage sensors
and multiple components of the NHEJ, BER, NER, and MMR
pathways are expressed in human oocytes (Menezo et al.,
2007), with a similar high expression of DNA repair proteins found
in human sperm (Galetzka et al., 2007), which suggest that GSCs
and gametes are well equipped to respond to DNA damage.
Accordingly, spermatogonia in Atm-deficient mice are progres-
sively lost, undergo meiotic arrest, accumulate DNA damage,
and lose their self-renewal potential in a p21-dependent manner
(Takubo et al., 2008).Mice expressing the hypomorphicmutation
of Rad50k22m also show severe attrition of spermatogonia, which
could be minimized by loss of p53 (Bender et al., 2002).Cell Stem Cell 8, January 7, 2011 ª2011 Elsevier Inc. 23
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to be around 16 days, with male GSCs being mostly kept in the
G0/G1 phase of the cell cycle. Consequently, NHEJ is the first line
of DNA repair in these cells. Interestingly, in vitro studies in mice
showed that spermatogonia are more sensitive to IR when they
are quiescent than when they are proliferating (Forand et al.,
2009; Moreno et al., 2001). In oogonia, the homologous chromo-
somes are close to each other and female GSCs preferentially
repair their DNA using HR (Baker, 1971). Mutations in the HR
repair pathway render female GSCs more susceptible to DNA-
damage-mediated cell death as shown by the increase sensi-
tivity to doxorubicin-induced apoptosis in oocytes from mice
deficient in Rad51 (Kujjo et al., 2010). Contrary to most SC pop-
ulations and somatic cells, the DDR in female GSCs does not
depend on p53. Instead, TAp63, an isoform of the p63 gene
and a p53 homolog, is constitutively expressed in oocytes and
is rapidly phosphorylated following DNA damage. Deletion of
TAp63 in mice results in a major increase in oocyte radioresist-
ance, consistent with the notion that TAp63 is the primary medi-
ator of DDR pathway in oocytes (Suh et al., 2006).
Mammary SCs
The mammary gland alternates between cycles of growth and
degeneration in relation to the estrus cycle. Mammary stem cells
(MaSCs) are responsible for homeostasis of the breast tissue
and for the massive tissue expansion and remodeling that
occurs during pregnancy and lactation (Visvader, 2009). MaSCs
have been isolated from mice and humans and represent multi-
potent SCs that have the ability to self renew as well as to differ-
entiate into ductal, alveolar, and myoepithelial cell lineages
(Ginestier et al., 2007; Shackleton et al., 2006; Stingl et al.,
2006). Breast cancer is the most common form of malignancies
in women. Mutations in genes involved in DNA repair such
as BRCA1 and BRCA2 are found in the majority of patients
with hereditary breast cancers, demonstrating the importance
of the HR-repair pathway in preventing the occurrence of
mammary tumors (Bradley and Medina, 1998). Mice deficient
for Brca1 are embryonic lethal, but mice with a conditional dele-
tion of Brca1 in the mammary epithelium are viable, display
severe abnormalities in mammary morphogenesis, and develop
undifferentiated breast cancers (Hakem, 2008). Knockdown of
BRCA1 in human MaSCs leads to a decrease of differentiated
luminal cells and an increase in cells with SC characteristics,
which suggests that BRCA1 is required for normal MaSC differ-
entiation and that BRCA1 loss may result in the accumulation of
genetically unstable MaSCs that are susceptible to cancer
development (Liu et al., 2008).
While the role of DNA repair in mammary development, main-
tenance, and prevention of breast tumors is well established, the
mechanisms underlying the DDR in MaSCs have only just begun
to emerge. Mouse MaSCs are more radioresistant than their
differentiated progeny, and their numbers increase following
IR (Woodward et al., 2007). Interestingly, MaSCs present less
DNA damage and rapidly activate the Wnt/b-catenin signal-
ing pathway following IR. Furthermore, increasing b-catenin
signaling by overexpression of Wnt1 or stabilized b-catenin
increases the survival of MaSCs following DNA damage, indi-
cating that Wnt/b-catenin signaling is an important component
of the DDR in MaSCs that may promote MaSC survival through
upregulation of survivin, a direct Wnt/b-catenin target gene24 Cell Stem Cell 8, January 7, 2011 ª2011 Elsevier Inc.(Chen et al., 2007; Woodward et al., 2007). It would certainly
be interesting to determine whether the selective activation of
Wnt/b-catenin pathway observed in MaSCs also occurs in other
tissue-specific SCs and promotes their survival following DNA
damage. Another mechanism that might promote MaSCs resis-
tance to DNA damage is their low level of ROS compared their
differentiated progeny (Diehn et al., 2009).
DNA-Damage Response in Cancer Stem Cells
A number of human cancers, including leukemia, glioblastoma,
breast, and skin cancers, contain cells with higher clonogenic
potential that are capable of reforming the parental tumors
upon transplantation. These cells functionally resemble tissue-
specific SCs, albeit with aberrant self-renewal and differentiation
abilities, and have been collectively referred to as cancer SCs
(CSCs), despite their variable developmental origin (Clarke and
Fuller, 2006; Jordan et al., 2006). It has been suggested that
CSCs are responsible for disease progression and tumor relapse
after therapy. Recent studies indicate that CSCs may take
advantage of the mechanisms of DNA repair used by tissue-
specific SCs to mediate resistance to chemo- and radiotherapy.
CSCs in Leukemia
Leukemias are cancers of the blood system, which often arise
due to deregulated HSC functions or acquisition of extended
self-renewal capabilities by more mature progenitor cells
(Passegue, 2005). Leukemia CSCs exist in acute myeloid
leukemia (AML) and chronic myelogenous leukemia (CML) and
have been shown to be more resistant to cancer therapies
than the bulk of the leukemia cells, indicating that their survival
may be responsible for disease persistence and cancer relapse
(Elrick et al., 2005; Jordan et al., 2006). Leukemia CSCs also use
to their advantage some protective mechanisms of HSCs,
including quiescent cell-cycle status, localization to a hypoxic
niche, and DDR mechanisms, to specifically escape chemo-
and radiotherapy that kill the bulk of the tumor cells (Guzman
and Jordan, 2009).
CML is a two-stage blood disease caused by the acquisition of
the chromosomal translocation fusion product BCR/ABL in
HSCs, which can be separated into chronic and acute phases.
The transition from chronic to acute disease is still poorly under-
stood, but the presence of DNA damage and the acquisition of
additional chromosomal aberrations resulting in overall genomic
instability in both HSCs and their downstream progeny is
believed to play a critical role in this transition (Burke and Carroll,
2010). BCR/ABL expression increases intracellular ROS levels,
which in turn enhances oxidative stress and DNA damage
and deregulates DNA repair mechanisms, thereby promoting
unfaithful and/or inefficient DNA repair leading to mutations
and chromosomal aberrations (Perrotti et al., 2010). Malfunction-
ing MMR, mutagenic NER, and compromised DSB repair (both
HR and NHEJ) are all hallmarks of cells expressing BCR/ABL
(Burke and Carroll, 2010; Deutsch et al., 2001; Slupianek et al.,
2002, 2006). Once DNA damage occurs, BCR/ABL-mediated
signaling can also inhibit apoptosis, thereby allowing cells to
survive DNA damage with which they normally would not be
able to cope (Burke and Carroll, 2010; Deutsch et al., 2001;
Slupianek et al., 2002, 2006). The genomic instability induced
by BCR/ABL has major implications for the pathogenesis and
treatment of CML since it can facilitate disease progression
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resistance against the current drugs used to treat CML (tyrosine
kinase inhibitors such as imatinib). Indeed, evolution from HSC-
derived CSCs to myeloid progenitor-derived CSCs has been
observed during the transition to myeloid blast crisis in human
CML and has been linked to activated mutations in the Wnt/
b-catenin pathway and acquisition of aberrant self-renewal
activity in HSC progeny (Rice and Jamieson, 2010). Preventing
oxidative stress and correcting defects in DNA repair pathways
in BCR/ABL-expressing CSCs at all stages of the disease may
therefore be beneficial to limit the acquisition of drug resistance
and slow down CML progression (Koptyra et al., 2006; Perrotti
et al., 2010).
Leukemia CSCs maintain some of the same protective mech-
anisms as normal HSCs. CSCs in both CML and AML have been
found to be quiescent (Elrick et al., 2005; Guan et al., 2003; Ishi-
kawa et al., 2007), suggesting that cell-cycle restriction is one of
the protective mechanisms that leukemia CSCs utilize to their
advantage (Guzman and Jordan, 2009). Indeed, human AML
CSCs transplanted into immunodeficient mice use quiescence
as a protective mechanism against chemotherapy (Saito et al.,
2010). When these cells are induced to exit quiescence and to
enter the cell cycle by treating the mice with the cytokine
G-CSF, AML CSCs become more sensitive to chemotherapy
and are effectively eliminated in vivo. Leukemia CSCs are also
able to co-opt other mechanisms used by normal HSCs for their
protection, such as p53-mediated induction of p21 and resulting
growth arrest that has recently been found to be critical in pro-
tecting adult HSCs from IR (Mohrin et al., 2010). Expression of
the PML/RAR or AML1/ETO fusion oncoproteins in murine
HSCs induces high levels of DNA damage and activates a p21-
dependent cell-cycle arrest in AML CSCs, which allows them
to repair excessive DNA damage and to escape apoptosis,
thereby maintaining their leukemic self-renewal capacity (Viale
et al., 2009). While it may seem paradoxical that a leukemia-initi-
ating oncogene promotes cell-cycle arrest instead of prolifera-
tion, the hijacking of such a protective mechanism provides
a strong selective advantage to the CSCs. In the absence of
p21, AML CSCs were more sensitive to replicative and thera-
peutic stress, and p21 null HSCs expressing PML/RAR or
AML1/ETO were unable to transplant the disease into recipient
mice, indicating a failure to maintain CSC activity (Viale et al.,
2009).
CSCs in Breast Cancer
The first evidence that solid tumors also contained cells with
CSC properties came with the demonstration that in human
breast cancer, CD44+CD24/lo cells are more clonogenic and,
when transplanted in immunocompromized mice, are able to
generate tumors that recapitulate the parental disease (Al-Hajj
et al., 2003). Transcriptional profiling of murine mammary gland
CSCs revealed increased expression of many DDR and DNA
repair associated genes (Zhang et al., 2008), suggesting that
mammary gland CSCs might be more resistant to chemo- and/
or radiotherapy. Comparison of tumor biopsies before and
after neoadjuvant chemotherapy showed an increase in the
proportion of mammary gland CSCs with mammosphere-form-
ing capacity following chemotherapy, hence confirming that
mammary gland CSCs are more resistant to chemotherapy (Li
et al., 2008; Shafee et al., 2008). Like normal MaSCs, mammarygland CSCs harbor lower levels of ROS compared to the rest of
the tumor cells, due to increased levels of genes regulating free
radical scavenging systems, such as those of the glutathione
metabolism. Mammary gland CSCs from human xenografts
(Phillips et al., 2006) or MMTV-Wnt1 tumor-bearing mice (Diehn
et al., 2009) exhibited higher survival upon IR treatment. Consis-
tent with the fact that ROS levels control IR-induced DNA
damage and apoptosis in CSCs, inhibition of glutathione metab-
olism decreased the clonogenic potential and sensitized
mammary gland CSCs to IR (Diehn et al., 2009). Furthermore,
p53-deficient mammary gland CSCs show accelerated DNA
repair activity as well as high Akt and Wnt signaling activity,
which promotes CSC survival following IR treatment (Zhang
et al., 2010). Interestingly, administration of an Akt inhibitor
inhibits b-catenin signaling and sensitizes mammary gland
CSCs to radiotherapy.
Understanding the role of DNA repair genes in the pathogen-
esis of breast cancer has been exploited for the development
of novel anticancer strategies. Tumors derived from Brca1-defi-
cient cells are extremely sensitive to the inhibition of PARP,
which plays an important role in the repair of single-strand
breaks by the BER pathway. In the absence of Brca1 and HR-
mediated DNA repair, persistent single-strand breaks need to
be repaired by the BER pathways, and as a consequence, inhi-
bition of PARP blocks this alternative pathway of DNA repair,
inducing cell death preferentially in cancer cells. A PARP inhibitor
prolonged disease-free survival when administered alone or in
combination with chemotherapeutic drugs in a mouse model
of brca1-deficient mammary gland tumors (Rottenberg et al.,
2008) and also exhibits clinical efficacy in human breast cancers
(Fong et al., 2009).
CSCs in Glioblastoma
Glioblastoma multiform (GBM) represents the most aggressive
type of brain tumor. The standard treatment combines surgery
and radiotherapy, but still, most patients relapse after therapy,
with a median survival of less than 12 months (Prados and Levin,
2000). CSCs from human glioblastoma have been isolated
based on the expression of prominin (CD133) (Singh et al.,
2004). Irradiation of human GBM xenografts led to increased
proportions of CD133+ cells, indicating that CSCs may be
responsible for tumor relapse after radiotherapy (Bao et al.,
2006). CSCs from GBM are more resistant to IR-induced cell
death compared to non-CSCs and show more robust activation
of DNA-damage checkpoint proteins, including ATM, Chk1, and
Chk2, as well as more efficient DNA repair activity. Importantly,
treatment with inhibitors of Chk1 and Chk2 kinases sensitizes
CSCs to IR-induced cell death, suggesting that inhibition of
DNA-damage checkpoint in CSCs may improve the efficiency
of radiotherapy in GBM (Bao et al., 2006). However, this increase
in DNA repair activity was not observed in all glioma-derived cell
lines (Ropolo et al., 2009), and loss of Chk2 instead potentiates
GBM radioresistance in mice (Squatrito et al., 2010), indicating
that this characteristic may be related to certain glioblastoma
subtypes. Moreover, glioma stem cell-like cells have been
shown to exhibit elevated levels of the antiapoptotic protein
Mcl1 that contributes to their radioresistance (Tagscherer
et al., 2008). Temozolomide, the most commonly used chemo-
therapy in the treatment of GBM that induces cell death by trig-
gering the methylation of guanine at position 6, which can beCell Stem Cell 8, January 7, 2011 ª2011 Elsevier Inc. 25
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induced CSC depletion in MGMT-negative, but not in MGMT-
positive, GBM (Beier et al., 2008).
Future Directions
The study of DDR in different types of tissue-specific SCs has
clearly highlighted the existence of common mechanisms acting
in certain adult SC populations to limit the amount of DNA
damage, to restrain them from undergoing massive apoptosis
and being exhausted following DNA damage, and to preserve
overall tissue function. These protective mechanisms may
have a cost for these tissue-specific SC populations, such as
blood HSCs and hair follicle BSCs, as they preserve immediate
survival at the expense of long-term maintenance of genomic
integrity, which may lead to aging, tissue atrophy, and/or cancer
development. Further studies are required to fully understand
and ultimately prevent the long-term deleterious consequences
of these protective mechanisms. In contrast, some tissue-
specific SCs, such as intestinal SCs, are not well protected
and undergo massive death after DNA damage. More studies
are needed to better understandwhy someSCs prefer to commit
suicide after DNA damage while others decide to survive, as well
as to understand how altruistic suicide might provide a selective
advantage to overall tissue function and what molecular mecha-
nisms dictate these very different outcomes.
Most of the studies on DDR in tissue-specific SCs have been
performed in adult animals during normal, or homeostasic,
conditions. Since the activity and relative quiescence of SCs
varies considerably during organogenesis, adult homeostasis,
and tissue repair following injuries, the consequence of DNA
damage might be very different in SCs at different ontogenic
stages or levels of activity, as it has now been shown for fetal
and adult HSCs. During organogenesis and tissue regeneration,
SCs divide more frequently, whereas during homeostasis,
SCs are more quiescent. Since different mechanisms of DNA
repair are used depending on the cell-cycle stage of the
damaged cells, are HR and NHEJ repair pathways differentially
important to preserve SC fitness depending on their activation
state? Are DNA repair-associated genes differentially activated
during morphogenesis, homeostasis, and regeneration? Do
mice with defective NHEJ or HR repair genes present different
phenotypes when these genes are ablated during embryonic
development compared to adult life? Future investigations are
needed to fully comprehend the role of these different DNA repair
mechanisms in SC biology.
In addition to the conserved set of genes that act in DDR and
DNA repair pathways, some miRNAs have recently been shown
to be induced by p53 in response to DNA damage and play an
important role in DDR outcomes of survival versus apoptosis
by interacting with key tumor-suppression networks (He et al.,
2007). Irradiation of cultured cells uncovered the involvement
of miR-34a in promoting apoptosis (Chang et al., 2007) and of
miR-192 and miR-215 in cell-cycle arrest induction (Georges
et al., 2008). Moreover, miR-34a is lost in several cancer cell
lines (Chang et al., 2007). Future studies will determine whether
DNA damage and repair-associated miRNAs are differentially
expressed in tissue-specific SCs compared to their differenti-
ated progeny and whether these miRNAs modulate the DDR in
different types of tissue-specific and cancer SCs. Another26 Cell Stem Cell 8, January 7, 2011 ª2011 Elsevier Inc.important question is whether CSCs from different types of
cancer also exhibit a survival advantage following chemo- and
radiotherapy. If so, is this resistance related to enhanced DNA
repair mechanisms or higher expression of antiapoptotic
factors? Do CSCs retain the DNA repair properties of the SCs
of their tissue of origin, or do they acquire functionally similar
characteristics during cancer progression through a selective
pressure? Do DDR abnormalities in CSCs versus bulk cancer
cells account for the vast genomic instability present within the
bulk of the tumors? Progresses in next generationwhole genome
sequencing and further studies of defined CSC populations will
be needed to assess how defects in their DDR contribute to
cancer evolution and associated genomic or base-pair level
changes.
Addressing these open questions will have profound implica-
tions for our understanding of how tissue-specific SCs respond
to DNA damage and maintain the integrity of their genome, how
deregulation of these mechanisms leads to cancer and aging,
how CSCs respond to chemo- and radiotherapy, and how these
characteristics may be exploited to increase the efficacy of
current anticancer treatments.
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